Penumbra (PEN) shareholders have formally approved the proposed acquisition by Boston Scientific (BSX), removing one of the last major contingent risks in the deal process. Penumbra reported $1.4B in revenue for FY2025, up 17.5% year-over-year, with a solid 67.1% gross margin — a high-quality neurovascular and vascular asset that justified BSX's interest. Boston Scientific itself posted $20.1B in revenue, growing nearly 20% YoY, underscoring its capacity to absorb and integrate a mid-cap MedTech like Penumbra.

The shareholder vote is a pivotal de-risking event for deal-spread traders. PEN shares will now trade much closer to the deal price, leaving minimal upside unless the spread has not fully closed. BSX bears the integration risk and the capital outlay, but gains a fast-growing neurovascular platform that complements its existing portfolio.

For deal-spread players, the key remaining catalyst is regulatory approval — any DOJ or FTC scrutiny of the neurovascular device market could delay or complicate closing. BSX's strong revenue growth and margins suggest it can manage the acquisition without diluting its own financial profile materially, but any deal premium it paid will weigh on near-term EPS accretion math.

The practical trade here is narrow: PEN arbitrage spread against the announced deal price, with residual risk only from regulatory disruption. BSX's own stock is more of a longer-duration story around integration success and whether Penumbra's 17.5% revenue growth trajectory is preserved post-close.